Fosun Pharma renews financial services deal with related party Fosun Finance

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has renewed its Financial Services Agreement with Fosun Finance, a subsidiary of its controlling shareholder, Fosun High Tech. The three-year agreement is effective January 1, 2026, until December 31, 2028, and constitutes a continuing connected transaction under Hong Kong Listing Rules. The renewed agreement includes comprehensive credit, deposit, settlement, and other financial services.

Under the agreement, Fosun Finance will provide a comprehensive credit facility of up to 2.0 bn yuan. The maximum daily balance of deposits placed by the Group with Fosun Finance will not exceed 2.0 bn yuan. Additionally, the aggregate service fee for settlement and other financial services will not exceed 1m yuan annually.

Historical transaction amounts for credit facilities used by the Group were 433.83m yuan in 2023 and 1,789.80m yuan in 2024, with 1,915.30m yuan for the six months ended June 30, 2025. Deposit balances were 1,989.39m yuan in 2023, 1,899.86m yuan in 2024, and 1,833.64m yuan for the six months ended June 30, 2025. The annual caps for 2026-2028 are set at 2.0 bn yuan for both credit limits and daily deposit balances, and 1m yuan for fees.